Compare IDEXX Laboratories, Inc. (IDXX) vs Novagold Resources Inc. (NG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Novagold Resources Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $532.96 (market cap $40.99B), while Novagold Resources Inc. trades at $6.32 (market cap $2.90B). The key difference: IDEXX Laboratories, Inc. is far larger — about 14.1× Novagold Resources Inc.'s market cap, and IDEXX Laboratories, Inc. is more actively traded (445,410 versus 3,973,464). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 47 Days and Novagold Resources Inc. for 0 Days on average.
| IDXX | NG | |
|---|---|---|
Market Cap | $40.99B | $2.90B |
Volume | 445,410 | 3,973,464 |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $14.20 |
52-Week Low | $504.70 | $5.18 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $41.89B | $2.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $529.01, up 0.97% with strong fundamental performance including 25.03% net income margin and consistent earnings beats. The stock shows neutral technical signals with support at $518 and resistance at $528. Recent acquisitions like CoVetAI and diagnostic platform expansions demonstrate strategic growth initiatives. Revenue grew from $3.9B in 2024 to $4.3B in 2025 with profit margins expanding to 24.61%.
Outlook remains positive with 56.5% analyst buy ratings and $665 consensus price target representing 25.7% upside. Key risks include FX headwinds and weaker U.S. vet visits, but strong recurring revenue and diagnostic innovation pipeline support long-term growth framework. The company's premium valuation (P/E 36.56) reflects market confidence in sustained profitability.
NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.
The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Novagold Resources Inc.
NovaGold Resources Inc. is a mineral exploration and development company that holds a majority interest in the Donlin Gold project, an undeveloped gold deposit in Alaska.
Read more on NG →
